Krazati (adagrasib)

P2, N=29, Not yet recruiting, Roswell Park Cancer Institute

However, pioneering work by Shokat and colleagues has led to the discovery of KRAS G12C-GDP mutant specific inhibitors, with two such inhibitors adagrasib and sotorasib now FDA approved for treatment of non-small cell lung cancer (NSCLC). Recent studies support the view that integration of AI algorithms with experimental methods is a key aspect in stream-lining the drug discovery process and identifying molecules with greater structural diversity, less off target effects than traditional screening methods. Furthermore, the authors believe that AI will eventually become standardized in drug discovery and existing pipelines specific to KRAS mutant inhibitor design will be expanded for additional KRAS mutations as well as other aggressive driver oncogenes across multiple cancers.

P2, N=535, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Sep 2026 --> Apr 2026

P2, N=50, Active, not recruiting, Alliance for Clinical Trials in Oncology | Suspended --> Active, not recruiting | N=186 --> 50

P1, N=1, Terminated, M.D. Anderson Cancer Center | N=52 --> 1 | Trial completion date: Dec 2026 --> Mar 2026 | Recruiting --> Terminated; Sponsor discontinued the trial

P1, N=300, Recruiting, Kura Oncology, Inc. | N=66 --> 300

P2, N=30, Recruiting, Ryan Gentzler, MD | Trial completion date: Aug 2028 --> Feb 2028 | Trial primary completion date: Mar 2026 --> Feb 2027

Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis-with no significant differences between patients who held or continued inhibitors during radiotherapy. Estimated 6-month cumulative incidence of local failure was 5%.

P1, N=52, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2030 --> Dec 2026

A 58-year-old man with KRAS-G12C-mutated stage IVB lung adenocarcinoma initiated first-line treatment with carboplatin + pemetrexed + pembrolizumab...Intravenous methylprednisolone led to rapid defervescence and biochemical improvement...Thereafter, he initiated adagrasib, achieving a durable partial response. This case illustrates discordance between metabolic quiescence and later structural damage in immune checkpoint inhibitor-associated aortitis. This supports long-term structural surveillance, as 18F-FDG PET/CT normalization does not guarantee structural safety.

When combined with EGFR inhibitors (osimertinib and gefitinib) in PC9 cells, the mimics showed a higher rate of growth inhibition compared with the controls and reduced IC50 values. Similarly, conmiR-15/107 enhanced growth inhibition by the KRAS inhibitors sotorasib and adagrasib in H358 cells...Long-term assays showed that the mimics reduced the survival and delayed the proliferation of DTPs in osimertinib-treated PC9 cells as well as sotorasib-treated H358 cells. These findings support conmiR-15/107 as a potential adjunct to targeted therapy, capable of enhancing treatment efficacy and delaying resistance in lung adenocarcinoma.

P2, N=200, Active, not recruiting, Mirati Therapeutics Inc. | Recruiting --> Active, not recruiting